A carregar...

Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD

<p>Abstract</p> <p>Background</p> <p>As chronic obstructive pulmonary disease (COPD) is a heterogeneous disease it is unlikely that all patients will benefit equally from a given therapy. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, has been shown to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Goehring Udo M, Calverley Peter MA, Rennard Stephen I, Bredenbröker Dirk, Martinez Fernando J
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2011-01-01
Colecção:Respiratory Research
Acesso em linha:http://respiratory-research.com/content/12/1/18
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!